mRNA Vaccines and Therapeutics
Simplify your start to in vitro transcription
Developing next-generation therapeutics and vaccines using mRNA requires starting materials that meet the highest standards for yield and safety. Our opDNA® template offers a breakthrough solution removing complexity and risk to your manufacturing process compared to plasmid DNA.
Discover opDNA® template technology
The cell-free template that delivers increased yields, unparalleled purity and polyA stability
opDNA® is a construct with a 3’ stabilized open end, which feeds directly into in vitro transcription (IVT) reactions. This feature means it doesn’t require additional enzymatic linearization or de-ending steps, simplifying your mRNA manufacturing workflows. Thanks to our unique cell-free manufacturing process, long, continuous polyA tails can be directly encoded into the DNA template. This allows you to avoid the risk of batch failures and the need for additional enzymatic tailing steps, which is often seen with plasmid-based workflows.
Let our DNA experts customize a solution just for you.
opDNA® platform: engineered for performance and safety
Traditional mRNA production often relies on DNA templates derived from plasmid backbones, which introduce variability and regulatory risk, as well as enzymatic steps for linearization and polyA tailing.
Our unique opDNA® platform fundamentally improves the core of your mRNA synthesis:
Highest Purity, Unmatched Safety: Unlike competitors that rely on plasmid backbones, our unique cell-free manufacturing process eliminates the risk of host-cell contamination and removes antibiotic resistance genes. This ensures the highest safety and regulatory compliance for your advanced therapeutic products.
Streamline Manufacturing: The opDNA® construct comes with a 3’ open-end, allowing you to simply start your IVT reactions without the need for further optimization or enzymatic steps.
Increased Yields: This optimized, high-fidelity template has been shown to increase mRNA yields with less DNA input compared to traditional plasmid DNA, allow you to manage cost and timelines.
Integrated PolyA Sequence: Encode long, continuous polyA sequences directly into the template and remove the need for a separate, error-prone enzymatic tailing step, simplifying your workflow and boosting consistency.
Critical quality attributes that matter
Achieve equivalent IVT mRNA yields at lower DNA inputs
Enhancing efficiency and reducing costs of your IVT reactions is crucial for mRNA therapeutic development. When compared to plasmid DNA, opDNA® achieves improved IVT yields for equivalent DNA mass. This is driven by the lack of bacterial backbone sequences in opDNA®, which only contain the sequence of interest from promoter to polyA tail.
Reduce dsRNA content vs traditional pDNA templates
Double-stranded RNA (dsRNA) is a major impurity in mRNA manufacturing, it can trigger strong innate immune responses, leading to reduced therapeutic efficacy and increased reactogenicity. dsRNA levels were measured using the J2 monoclonal antibody–based dot blot assay showing comparable levels of dsRNA between opDNA® and plasmid DNA-derived mRNA.
Improve PolyA stability with opDNA® templates
PolyA stability is often a challenge in fermentation-based manufacturing processes, 4basebio’s cell-free manufacturing allows for long polyA tails to be directly encoded into the DNA template. A full length polyA tail of up to 180bp can be encoded into the template and be fully maintained through amplification. A single peak of the expected length can be detected by capillary gel electrophoresis (+/- 5%).
Learn more about opDNA® technology with our recent white paper
Applications
Find out more about our enzymatic manufacturing process and the benefits of synthetic DNA.
Custom Manufacturing
Discover our RUO, HQ, and GMP-grade synthetic DNA, designed for every stage, from discovery to commercial production